Metabolic syndrome loses its predictive power in late-stage chronic kidney disease progression - A paradoxical phenomenon

Clinical Nephrology

Volumn 75, Issue 2, 2011, Pages 141-149

  Lee, C C ^a,b   Sun, C Y ^a,b   Wu, I W ^a,b   Wang, S Y ^b   Wu, M S ^a,b  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Chronic kidney disease; Diabetes mellitus; Metabolic syndrome

Indexed keywords

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; DIABETES MELLITUS; DISEASE COURSE; FEMALE; FOLLOW UP; HAZARD RATIO; HEMODIALYSIS; HUMAN; HYPERTENSION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PERITONEAL DIALYSIS; PREDICTION; RENAL REPLACEMENT THERAPY;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CHRONIC DISEASE; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY DISEASES; LONGITUDINAL STUDIES; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; RISK FACTORS; TAIWAN; TIME FACTORS;

EID: 79251499295     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP75141     Document Type: Article

References (36)

1. Reaven GM. Insulin resistance and human disease: a short history. J Basic Clin Physiol Pharmacol. 1998; 9: 387-406.
2. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991; 14: 173-194.
3. Ford ES, Giles WH, Mokdad A. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care. 2004; 27: 2444-2449.
4. Nestel P, Lyu R, Low LP, Sheu WH, Nitiyanant W, Saito I, Tan CE. Metabolic syndrome: recent prevalence in East and Southeast Asian populations. Asia Pac J Clin Nutr. 2007; 16: 362-367.
5. Festa A, D'Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000; 102: 42-47. (Pubitemid 30430551)
6. Langenberg C, Bergstrom J, Scheidt-Nave C, Pfeilschifter J, Barrett-Connor E. Cardiovascular death and the metabolic syndrome: role of adiposity-signaling hormones and inflammatory markers. Diabetes Care. 2006; 29: 1363-1369.
7. Koh KK, Han SH, Quon MJ. Inflammatory markers and the metabolic syndrome insights from therapeutic interventions. J Am Coll Cardiol. 2005; 46: 1978-1985.
8. Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB Jr, Wilson PW. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation. 2004; 110: 380-385.
9. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005; 112: 3066-3072.
10. Pischon T, Hu FB, Rexrode KM, Girman CJ, Manson JE, Rimm EB. Inflammation, themetabolic syndrome, and risk of coronary heart disease in women and men. Atherosclerosis. 2008; 197: 392-399.
11. Gelber RP, Kurth T, Kausz AT, Manson JE, Buring JE, Levey AS, Gaziano JM. Association between body mass index and CKD in apparently healthy men. Am J Kidney Dis. 2005; 46: 871-880. (Pubitemid 41505461)
12. Sarafidis PA, Ruilope LM. Insulin resistance, hyperinsulinemia, and renal injury: mechanisms and implications. Am J Nephrol. 2006; 26: 232-244.
13. Peralta CA, Kurella M, Lo JC, Chertow GM. The metabolic syndrome and chronic kidney disease. Curr Opin Nephrol Hypertens. 2006; 15: 361-365.
14. Kaysen GA. Hyperlipidemia in chronic kidney disease. Int J Artif Organs. 2007; 30: 987-992.
15. Ritz E. Metabolic syndrome and kidney disease. Blood Purif. 2008; 26: 59-62.
16. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, Whelton PK, He J. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004; 140: 167-174. (Pubitemid 38155647)
17. Zhang L, Zuo L, Wang F, Wang M, Wang S, Liu L, Wang H. Metabolic syndrome and chronic kidney disease in a Chinese population aged 40 years and older. Mayo Clin Proc. 2007; 82: 822-827.
18. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among non-diabetic adults. J Am Soc Nephrol. 2005; 16: 2134-2140.
19. Wu IW, Wang SY, Hsu KH, Lee CC, Sun CY, Tsai CJ, Wu MS. Multidisciplinary predialysis education decreases the incidence of dialysis and reduces mortality - a controlled cohort study based on the NKF/DOQI guidelines. Nephrol Dial Transplant. 2009; 24: 3426-3433.
20. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999; 130: 461-470.
21. Ruggenenti P, Gaspari F, Perna A, Remuzzi G. Cross sectional longitudinal study of spot morning urine protein: creatinine ratio, 24-hour urine protein excretion rate, glomerular filtration rate, and end-stage renal failure in chronic renal disease in patientswithout diabetes.BMJ. 1998; 316: 504-509.
22. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106: 3143-3421.
23. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis. 2002; 39 (Suppl 1): S1-S246.
24. Essig M, Escoubet B, de Zuttere D, Blanchet F, Arnoult F, Dupuis E, Michel C, Mignon F, Mentre F, Clerici C, Vrtovsnik F. Cardiovascular remodelling and extracellular fluid excess in early stages of chronic kidney disease. Nephrol Dial Transplant. 2008; 23: 239-248.
25. McClellan WM, Flanders WD. Risk factors for progressive chronic kidney disease. J Am Soc Nephrol. 2003; 14 (Suppl 2): S65-S70.
26. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care. 2005; 28: 1769-1778.
27. Lea J, Cheek D, Thornley-Brown D, Appel L, Agodoa L, Contreras G, Gassman J, Lash J, Miller ER 3rd, Randall O, Wang X, McClellan W. Metabolic syndrome, proteinuria, and the risk of progressive CKD in hypertensive African Americans. Am J Kidney Dis. 2008; 51: 732-740.
28. Alexander MP, Patel TV, Farag YM, Florez A, Rennke HG, Singh AK. Kidney pathological changes in metabolic syndrome: a cross-sectional study. Am J Kidney Dis. 2009; 53: 751-759.
29. Levin A. Identification of patients and risk factors in chronic kidney disease - evaluating risk factors and therapeutic strategies. Nephrol Dial Transplant. 2001; 16 (Suppl 7): 57-60.
30. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med. 1999; 341: 1127-1133.
31. Lee CC, Sun CY, Wu MS. Long-term modality-related mortality analysis in incident dialysis patients. Perit Dial Int. 2009; 29: 182-190.
32. Luk AO, So WY,Ma RC, Kong AP, Ozaki R, Ng VS, Yu LW, Lau WW, Yang X, Chow FC, Chan JC, Tong PC. Metabolic syndrome predicts new onset of chronic kidney disease in 5,829 patients with type 2 diabetes: a 5-year prospective analysis of the Hong Kong Diabetes Registry. Diabetes Care. 2008; 31: 2357-2361.
33. Whaley-Connell A, Sowers JR, McCullough PA, Roberts T, Mc Farlane SI, Chen SC, Li S, Wang C, Collins AJ, Bakris GL. Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis. 2009; 53 (Suppl 4): S11-S21.
34. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005; 353: 238-248. (Pubitemid 41058323)
35. Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Grönhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Süleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wüthrich RP, Gottlow M, Johnsson E, Zannad F. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009; 360: 1395-1407.
36. Froissart M, Rossert J, Jacquot C, Paillard M, Houillier P. Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol. 2005; 16: 763-773.